Compare · MOH vs NTRA
MOH vs NTRA
Side-by-side comparison of Molina Healthcare Inc (MOH) and Natera Inc. (NTRA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MOH and NTRA operate in Medical Specialities (Health Care), so they compete in similar markets.
- NTRA is the larger of the two at $56.90B, about 5.2x MOH ($10.92B).
- NTRA has been more active in the news (11 items in the past 4 weeks vs 9 for MOH).
- Both have 25 recent analyst ratings on file.
- Company
- Molina Healthcare Inc
- Natera Inc.
- Price
- -
- -
- Market cap
- $10.92B
- $56.90B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2003
- 2015
- News (4w)
- 9
- 11
- Recent ratings
- 25
- 25
Molina Healthcare Inc
Molina Healthcare, Inc. provides managed health care services to low-income families and individuals under the Medicaid and Medicare programs and through the state insurance marketplaces. The company operates in two segments, Health Plans and Other. As of December 31, 2020, it served approximately 4.0 million members eligible for Medicaid, Medicare, and other government-sponsored healthcare programs in 15 states. The company offers its health care services for its members through contracts with a network of providers, including independent physicians and physician groups, hospitals, ancillary providers, and pharmacies. Molina Healthcare, Inc. was founded in 1980 and is headquartered in Long Beach, California.
Natera Inc.
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
Latest MOH
- Director Zoretic Richard C was granted 304 shares (SEC Form 4)
- Director Wolf Dale B was granted 304 shares (SEC Form 4)
- Director Schapiro Richard M was granted 304 shares, increasing direct ownership by 2% to 12,615 units (SEC Form 4)
- Director Romney Ronna was granted 304 shares (SEC Form 4)
- Director Orlando Steven J was granted 304 shares (SEC Form 4)
- Director Lockhart Stephen H was granted 304 shares, increasing direct ownership by 7% to 4,688 units (SEC Form 4)
- Director Grohowski Leo P was granted 304 shares, increasing direct ownership by 20% to 1,846 units (SEC Form 4)
- Director Soistman Francis S Jr was granted 304 shares, increasing direct ownership by 34% to 1,211 units (SEC Form 4)
- Director Brasier Barbara L was granted 304 shares, increasing direct ownership by 5% to 6,122 units (SEC Form 4)
- Molina Healthcare Announces Third Quarter 2026 Earnings Release and Conference Call Dates
Latest NTRA
- Natera’s Signatera™ MRD Test Named to TIME’s List of the Best Inventions of 2026
- Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer
- SEC Form 4 filed by Natera Inc.
- FDA Grants Breakthrough Device Designation for Natera’s Multi-Cancer Early Detection Assay
- Natera Announces Randomized, Signatera™-Guided Interventional Study in Melanoma
- New Signatera™ Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists
- Alliance Foundation Trials and Natera Announce AFT-70 NAVIGATE: a Global, Randomized, Phase III Trial Evaluating Genentech’s Oral Selective Estrogen Receptor Degrader (SERD) with Signatera™ MRD-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
- PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon sold $1,242,645 worth of shares (3,000 units at $414.22) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 106,914 units (SEC Form 4)
- CEO AND PRESIDENT Chapman Steven Leonard sold $526,144 worth of shares (1,273 units at $413.31) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 96,926 units (SEC Form 4)
- CO-FOUNDER Sheena Jonathan sold $7,008,972 worth of shares (18,064 units at $388.01) as part of a pre-agreed trading plan (SEC Form 4)